STOCK TITAN

InflaRx N.V. - IFRX STOCK NEWS

Welcome to our dedicated news page for InflaRx N.V. (Ticker: IFRX), a resource for investors and traders seeking the latest updates and insights on InflaRx N.V..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect InflaRx N.V.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of InflaRx N.V.'s position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
management
-
Rhea-AI Summary
InflaRx announces the commercial launch of Gohibic (vilobelimab) in the U.S. for the treatment of critically ill COVID-19 patients under an Emergency Use Authorization (EUA) granted by the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
covid-19
-
Rhea-AI Summary
WuXi Biologics partners with InflaRx for manufacturing COVID-19 treatment Gohibic (vilobelimab)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
partnership covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.46%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.67%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.67%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
83.9%
Tags
covid-19
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.67%
Tags
none
InflaRx N.V.

Nasdaq:IFRX

IFRX Rankings

IFRX Stock Data

88.32M
48.82M
7.34%
29.18%
0.66%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Germany
Jena

About IFRX

inflarx n.v., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using c5a technology primarily in the germany and united states. its c5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. the company's lead product candidate is ifx-1, an intravenously delivered first-in-class anti-c5a monoclonal antibody, which completed the phase iib clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat anca-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing ifx-1 for the treatment of oncological diseases. it also develops ifx-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. inflarx n.v. has co-development agreement with beijing defe